Under the oxygen-deficient environment of tumor, O6-(3-amino-benzyl) guanine acting as an AGT inhibitor is yielded via the reduction of the azo bond to aniline, and BCNU is fully released simultaneously, thus achieving an enhanced anticancer therapeutic efficacy. This evidence concerns the gene AGT and neoplasm.